Diabetes Technology Society

DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results

Retrieved on: 
Thursday, March 28, 2024
Nexus, DTS, Sanofi, Growth, Partnership, Diabetes, Webcast, Ratio, Research, Acquisition, Diabetes Technology Society, Prediabetes, Traction, Depreciation, GAAP, Hypertension, Total, Medicine, Marketing, Video game

NEW YORK, March 28, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.

Key Points: 
  • NEW YORK, March 28, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.
  • Gross profit as a percentage of revenues decreased to 3.7% in the fourth quarter of 2023, from 40.1% in the fourth quarter of 2022, and 17.3% in the third quarter of 2023.
  • Total operating expenses for the fourth quarter ended December 31, 2023, were $14.3 million compared with $11.7 million for the fourth quarter ended December 31, 2022, and $16.1 million for the third quarter of 2023, an increase of $2.6 million, or 22.2%, compared to the fourth quarter of 2022, and a decrease of $1.8 million, or 11.2%, compared to the third quarter of 2023.
  • Total operating expenses excluding stock-based compensation, acquisition expenses and depreciation for the fourth quarter of 2023 were $9.9 million compared to $10 million for the fourth quarter of 2022, and $10.9 million for the third quarter of 2023.

New Research Sheds Light on Mediators of Improved Outcomes in Dario Users

Retrieved on: 
Tuesday, November 21, 2023
Digital health, Diabetes Technology Society, ISPOR, Adherence (medicine), Sanofi, Research, Behavior, DTS, Medicine, Birth control, Medical imaging, Glycated hemoglobin

NEW YORK, Nov. 21, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new analyses recently presented by Sanofi U.S. demonstrating two mediators associated with improved clinical and economic in Dario users.

Key Points: 
  • NEW YORK, Nov. 21, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new analyses recently presented by Sanofi U.S. demonstrating two mediators associated with improved clinical and economic in Dario users.
  • Dario users saw an overall clinically significant reduction in HbA1c and an associated 10.6% improvement in medication adherence.
  • The new research helps explain the results of a previously reported study on reductions in HbA1c, because medication adherence is one behavioral component of self-care needed to achieve improved clinical outcomes.
  • These results showed that meaningful engagement activities and medication adherence are both important contributors to the better outcomes in Dario users."

Dario Publishes New Research Demonstrating that Dario Users That Increased Physical Activity Can Maintain Reduced Blood Glucose

Retrieved on: 
Monday, November 13, 2023
Diet, School, University of Haifa, Research, Health, University, Blood, Partnership, School of Public Health, Public health, Diabetes Technology Society, Diabetes, Prediabetes, Blood pressure, Medical device, Dario

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced new research presented at the Diabetes Technology Society 2023 Meeting on November 7, 2023. The new research demonstrated the value of associating physical activity tracking alongside blood sugar tracking for people living with diabetes and pre-diabetes.

Key Points: 
  • The new research demonstrated the value of associating physical activity tracking alongside blood sugar tracking for people living with diabetes and pre-diabetes.
  • The results demonstrated significantly reduced blood glucose levels in the first four months of using Dario and increased step levels in the same timeframe maintained for 12 months.
  • In addition, the results demonstrated clinically significant reductions in blood glucose levels in users who tracked at least 400 steps per day.
  • The research was conducted in partnership with the Integrative Pain Laboratory, School of Public Health at the University of Haifa.

Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes

Retrieved on: 
Monday, October 16, 2023
Cardiology, Technology, Diabetes, Health, Mental Health, Health Technology, Medical Devices, Apps, Applications, Software, Fitness & Nutrition, Telemedicine, Virtual Medicine, Type 2 diabetes, FRCP, A1C, Quality of life, Apple, Cognitive behavioral therapy, Better, Insurance, Medicine, Disease, Randomized controlled trial, FRCPE, FDA, Therapy, PDT, DM, Blood pressure, RCT, CBT, Digital health, Regulation of tobacco by the U.S. Food and Drug Administration, Diabetes Technology Society, Patient, Pharmaceutical industry, Health insurance, T2D, Bachelor of Medicine, Bachelor of Surgery

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced the commercial launch of AspyreRx , the first cognitive behavioral therapy (CBT) app to receive U.S Food and Drug Administration (FDA) authorization as a Class II device to treat adults with type 2 diabetes (T2D).

Key Points: 
  • Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced the commercial launch of AspyreRx , the first cognitive behavioral therapy (CBT) app to receive U.S Food and Drug Administration (FDA) authorization as a Class II device to treat adults with type 2 diabetes (T2D).
  • Licensed healthcare providers are now able to prescribe AspyreRx, and the app is available for download on the Apple App and Google Play Stores.
  • AspyreRx delivers a novel form of CBT developed by Better Therapeutics, specifically for the treatment of T2D.
  • During the initial launch phase, as the Company works on securing insurance coverage, eligible patients can access AspyreRx on a cash-pay basis for a limited time.

Better Therapeutics Receives FDA Authorization for AspyreRx™ to Treat Adults with Type 2 Diabetes

Retrieved on: 
Monday, July 10, 2023
Software, Research, General Health, Pharmaceutical, Technology, Infectious Diseases, Health Technology, Clinical Trials, Science, Biotechnology, FDA, Health, Diabetes, Psychology, Cognitive behavioral therapy, FRCP, De novo, DM, Overalls, FRCPE, Type 2 diabetes, PDT, Medicine, Better, Diabetes Technology Society, Food and Drug Administration Amendments Act of 2007, Digital health, HIV disease progression rates, Patient, Physician, Randomized controlled trial, Therapy, T2D, Food, Safety, Disease, Pharmaceutical industry, Diabetes Care

AspyreRx was reviewed through the FDA’s De Novo pathway and its authorization creates a new class of diabetes digital behavioral therapeutic devices.

Key Points: 
  • AspyreRx was reviewed through the FDA’s De Novo pathway and its authorization creates a new class of diabetes digital behavioral therapeutic devices.
  • “This De Novo authorization also provides a foundation for potential future growth opportunities.
  • AspyreRx is designed to address these barriers, leveraging technology to deliver an evidence-based therapeutic intervention to patients.
  • Investors and the general public may access a live webcast of the call by visiting https://edge.media-server.com/mmc/p/adggoags

Rimidi Showcases Addition of Glycemic Risk Index to Diabetes Management Platform, Announces Enhanced Integration with Dexcom

Retrieved on: 
Thursday, June 22, 2023
CGM, Data management, Hyperglycemia, Obesity, Kidney failure, Senior, Diabetes, Type 2 diabetes, Glucose, Doctor of Philosophy, TIR, Glycemia, Diabetes Technology Society, Blood, Hypoglycemia, GRI, MD, EHR, Patient, Risk, American Diabetes Association, Himawari (satellites), Health, Disease, Medical device, Pharmaceutical industry, Dexcom

ATLANTA, June 22, 2023 /PRNewswire-PRWeb/ -- Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, announced today enhancements to its diabetes management platform, including the addition of Glycemic Risk Index (GRI) as an emerging tool for patient and population outcomes management.

Key Points: 
  • Through the collaboration, glycemic control metrics will enable more proactive and personalized management of diabetes across populations to drive better care decisions.
  • Glycemic Risk Index : A new actionable metric for describing the quality of glycemia in CGM tracking, developed by the Diabetes Technology Society.
  • For more information on Rimidi and its newly enhanced diabetes management platform, visit rimidi.com/solutions/diabetes .
  • Members of the Rimidi and Dexcom teams will also be at the American Diabetes Association's 83rd Scientific Sessions 2023 in San Diego, CA from June 23-26.

Glucose Biosensors Market Report 2022: Increasing Demand for Self-Monitoring Devices Drives 14.45% Annual Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022
Diabetes, Health, Medical Devices, Diagnosis, CAGR, Diabetes Technology Society, User (computing), Technology, Prevalence, Projection, USD, Incidence, Diabetes, Region, Medical device

The "Glucose Biosensors Market Analysis, by Technology, by Product, by End Users and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glucose Biosensors Market Analysis, by Technology, by Product, by End Users and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The glucose biosensors market size is estimated to be USD 13,200 million in 2021 and is expected to witness a CAGR of 14.45% during the forecast period 2022-2029.
  • The globally increasing self-monitoring device demand, modernizations in glucose biosensor technology, and a growing proportion of people worldwide developing diabetes are some of the primary market drivers.
  • However, the strict regulatory framework and the high price of glucose biosensors are expected to restrain the market growth.

One Drop's Multi-Condition Program Achieves Third-Party Validation for Simultaneous Improvement of Blood Glucose and Blood Pressure Outcomes

Retrieved on: 
Wednesday, February 9, 2022
Hypertension, Depression, Prediabetes, Android, Overweight, Artificial intelligence, IOS, Health, Diabetes Technology Society, Multimedia, Deloitte Technology Fast 500, Algorithm, Apple Store, Best Buy, DTM, Third party, Blood, Program, Risk, Blood pressure, CVS, AHA, Organization, Gaps, Mark (given name), Diabetes, Machine learning, Walmart, Pharmaceutical industry, Medical device, Mobile phone, Amazon

The 2022 validation report verifies claims for One Drop's principal multi-condition studies demonstrating clinical outcomes for prediabetes, diabetes, and hypertension.

Key Points: 
  • The 2022 validation report verifies claims for One Drop's principal multi-condition studies demonstrating clinical outcomes for prediabetes, diabetes, and hypertension.
  • "For people living with multiple chronic conditions, like hypertension and diabetes, the Validation Institute's report confirms One Drop can impact multiple clinical outcomes simultaneously through one personalized program."
  • Validation Institute is an independent, objective, 3rd party organization on a mission to improve the quality and cost of healthcare.
  • The goal: empower everyone to take proactive action for better health outcomes, peak performance, and a more fulfilling life.

Senseonics Holdings, Inc. Reports Third Quarter 2021 Financial Results

Retrieved on: 
Tuesday, November 9, 2021
Diabetes, Health, Medical Devices, Safety, European Association for the Study of Diabetes, CGM, PMA, Eastern Time Zone, European Union, Doctor of Philosophy, Union, Investment, Telephone, COVID-19, Research, SENS, Diabetes Technology Society, Association, Conference, HCPS, NYSE, Review, Diabetes, Marketing, Patient, Risk, FDA, Total, Pharmaceutical industry

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended September 30, 2021.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended September 30, 2021.
  • Total revenue for the third quarter was $3.5 million compared to $0.8 million for the third quarter of 2020.
  • Third quarter 2021 sales and marketing expenses decreased by $0.7 million year-over-year, to $2.5 million.
  • Conference Call and Webcast Information:
    Company management will host a conference call at 4:30 pm (Eastern Time) today, November 9, 2021, to discuss these financial results and recent business developments.

Nemaura Medical to Present at the Diabetes Technology Society 2021 Conference on November 4, 2021

Retrieved on: 
Wednesday, November 3, 2021
2021 Essex County Council election, Q & A, NMRD, Diabetes Technology Society, CGM, NASDAQ, FDA, Prediabetes, Weight loss, Nemaura Medical, Company, CE, Diabetes, Artificial intelligence, PMA, GLOBE, Pharmaceutical industry, Medical device

To watch the presentation, participants must be registered for the conference, which can be found here.

Key Points: 
  • To watch the presentation, participants must be registered for the conference, which can be found here.
  • The Diabetes Technology Society meetings goal is to connect technology developers and users to facilitate the creation of new and cost-effective tools to help people with diabetes.
  • The format will include state-of-the-art lectures, oral presentations of abstracts, panel discussions with Q & A sessions, and virtual poster sessions.
  • Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.